 SAN DIEGO-- BUSINESS WIRE --Janux Therapeutics, Inc. Nasdaq: JANX Janux, a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager TRACTr and Tumor Activated Immunomodulator TRACIr platforms, today announced that Janux management will present at two upcoming investor conferences and be available for 1x1 meetings. Details of the presentations are as follows: 